Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and pharmacokinetics study of NT 0150
NL-OMON60655Phase 1Completed
- Sponsor
- NodThera
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of trabzanoflast in Alzheimer's disease (AD) and Parkinson's disease (PD), sponsored by NodThera. Started Sep 2025; status: completed.
02
Drugs
trabzanoflast
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON60655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60655.